Adamas Pharmaceuticals Inc (ADMS)
Common Stock
| MRQ (2021-9-30) | 2020 (2020-12-31) | 2019 (2019-12-31) | 2018 (2018-12-31) | 2017 (2017-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 78.62M | 71.70M | 65.80M | 56.60M | 91.30M | |||
| Marketable Securities | 4.47M | 11.70M | 66.80M | 154.30M | 82.10M | |||
| Receivables | 10.05M | 9.30M | 7.00M | 6.40M | 1.40M | |||
| Inventories | 8.68M | 7.30M | 5.30M | 5.10M | 1.70M | |||
| Other Current Assets | 6.18M | 11.80M | 5.40M | 6.10M | 2.60M | |||
| Total Current Assets | 108.00M | 111.70M | 150.30M | 228.40M | 179.20M | |||
| Non-Current Assets | ||||||||
| PPE Net | 6.86M | 8.30M | 10.50M | 3.70M | 3.10M | |||
| Investments And Advances | 27.99M | N/A | N/A | 0.00 | 3.00M | |||
| Intangibles | 687.00K | N/A | N/A | N/A | N/A | |||
| Other Non-Current Assets | 435.00K | 0.00 | 1.30M | 2.80M | 900.00K | |||
| Total Non-Current Assets | 35.98M | 8.30M | 11.90M | 6.40M | 7.00M | |||
| TOTAL ASSETS | 143.98M | 120.00M | 162.20M | 234.80M | 186.20M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 4.55M | 3.70M | 2.00M | 1.70M | N/A | |||
| Accrued Expenses | 12.96M | 29.00M | 17.80M | 15.50M | 12.40M | |||
| Accounts Payable | 4.21M | 2.10M | 6.90M | 6.60M | 3.90M | |||
| Other Current Liabilities | 2.12M | 0.00 | 200.00K | 500.00K | 300.00K | |||
| Total Current Liabilities | 23.84M | 34.90M | 26.90M | 24.30M | 16.60M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 124.48M | 126.30M | 125.70M | 117.50M | 102.60M | |||
| Other Non-Current Liabilities | 17.26M | 8.80M | 10.40M | 3.20M | 800.00K | |||
| Total Non-Current Liabilities | 141.74M | 135.10M | 136.20M | 120.60M | 103.50M | |||
| TOTAL LIABILITIES | 165.58M | 170.00M | 163.10M | 144.90M | 120.10M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -549.72M | -505.30M | -447.90M | -342.70M | -211.70M | |||
| Additional Paid In Capital | 528.05M | 455.30M | 446.90M | 432.80M | 278.00M | |||
| Common Shares | 50.00K | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | 13.00K | 0.00 | 0.00 | -300.00K | -200.00K | |||
| Shares Outstanding | 45.69M | 28.90M | 28.00M | 27.40M | 23.30M | |||
| Tangible Book Value per Share | -0.49 | -1.73 | -0.03 | 3.28 | 2.84 | |||
| Total Shareholders' Equity | -21.61M | -50.00M | -900.00K | 89.90M | 66.10M | |||
| TOTAL LIABILITIES AND EQUITY | 143.98M | 120.00M | 162.20M | 234.80M | 186.20M | |||
| Statistics | ||||||||
| Debt/Equity | -5.76 | -2.53 | -139.67 | 1.31 | 1.55 | |||
| Current Ratio | 4.53 | 3.20 | 5.59 | 9.40 | 10.80 | |||
| Return On Assets (ROA) | -43.55% | -47.83% | -64.85% | -55.79% | -48.06% | |||
| Return On Equity (ROE) | N/A | N/A | N/A | -145.72% | -135.39% | |||
| Return On Invested Capital (ROIC) | N/A | N/A | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash (ROICexc) | N/A | N/A | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | N/A | N/A | N/A | N/A | N/A | |||
All data in USD